UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

  Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
                                     of 1934


       Date of Report (Date of earliest event reported) November 30, 2005


                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)


Delaware                                 000-20985                 06-1226727
--------                                  ---------                ----------
(State or Other Jurisdiction)     (Commission File Number)      (I.R.S. Employer
of Incorporation)                                                Identification)


             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written  communication  pursuant to Rule 425 under the  Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 40.13e-4(c))

<PAGE>

ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

(a)    On November  30,  2005,  the  Registrant (the  "Company") entered into an
Amendment (the  "Amendment") to the 2005 Credit Facility  Agreement (the "Credit
Facility") between the Company and Marr Technologies, BV ("Marr"), the Company's
largest  stockholder,  amending certain terms of the Credit Facility dated April
4, 2005. Pursuant to the Amendment,  the term under which the Company may borrow
monies was extended to April 3, 2006 from  December 31, 2005.  The interest rate
for promissory notes issued under the Amendment was lowered to 7% per annum from
9% per annum.  The term of any  promissory  notes issued under the Amendment was
extended so that such promissory notes will become due on April 3, 2007, instead
of the  later of twelve  months  from the  issuance  date or May 31,  2006.  The
issuance of  promissory  notes under the  Amendment  will require  approval by a
majority of a quorum of the Company's Board of Directors,  instead of the entire
Board of  Directors.  The Company  granted to a Marr a security  interest in the
Company's  assets,  up to an  aggregate  maximum  of  $6,000,000,  to secure the
repayment of monies borrowed under the Amendment.  Proceeds from the issuance of
promissory notes under the Amendment may be used for general corporate purposes,
including investments in the Company's international subsidiaries.

      The Company hereby incorporates by reference the terms of the Amendment to
2005 Credit  Facility  which is annexed  hereto and made a part of this  current
report.

ITEM 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN OBLIGATION  UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

(a)   On November 30, 2005, the Company issued promissory notes to Marr pursuant
to the Amendment  described in Item 1.01 above in an aggregate  principal amount
of $1,500,000.  The promissory  notes bear interest at the rate of 7% per annum.
Principal and accrued interest thereunder are due and payable on April 3, 2007.

<PAGE>


ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS


      (c)   Exhibits


            Exhibit No.                Description
            -----------                -----------
            10.166           Amendment to 2005 Credit Facility.


<PAGE>

                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: Lake Oswego, Oregon
      December 6, 2005

                                       Calypte Biomedical Corporation

                                       By: /s/ Theodore R. Gwin
                                           ---------------------------
                                           Theodore R. Gwin
                                           Chief Financial Officer
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "051247204"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

  Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act
                                     of 1934

       Date of Report (Date of earliest event reported) November 30, 2005

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)

Delaware                                 000-20985                 06-1226727
--------                                  ---------                ----------
(State or Other Jurisdiction)     (Commission File Number)      (I.R.S. Employer
of Incorporation)                                                Identification)

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written  communication  pursuant to Rule 425 under the  Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 40.13e-4(c))
ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

(a)    On November  30,  2005,  the  Registrant (the  "Company") entered into an
Amendment (the  "Amendment") to the 2005 Credit Facility  Agreement (the "Credit
Facility") between the Company and Marr Technologies, BV ("Marr"), the Company's
largest  stockholder,  amending certain terms of the Credit Facility dated April
4, 2005. Pursuant to the Amendment,  the term under which the Company may borrow
monies was extended to April 3, 2006 from  December 31, 2005.  The interest rate
for promissory notes issued under the Amendment was lowered to 7% per annum from
9% per annum.  The term of any  promissory  notes issued under the Amendment was
extended so that such promissory notes will become due on April 3, 2007, instead
of the  later of twelve  months  from the  issuance  date or May 31,  2006.  The
issuance of  promissory  notes under the  Amendment  will require  approval by a
majority of a quorum of the Company's Board of Directors,  instead of the entire
Board of  Directors.  The Company  granted to a Marr a security  interest in the
Company's  assets,  up to an  aggregate  maximum  of  $6,000,000,  to secure the
repayment of monies borrowed under the Amendment.  Proceeds from the issuance of
promissory notes under the Amendment may be used for general corporate purposes,
including investments in the Company's international subsidiaries.

      The Company hereby incorporates by reference the terms of the Amendment to
2005 Credit  Facility  which is annexed  hereto and made a part of this  current
report.

ITEM 2.03 CREATION OF A DIRECT  FINANCIAL  OBLIGATION OR AN OBLIGATION  UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

(a)   On November 30, 2005, the Company issued promissory notes to Marr pursuant
to the Amendment  described in Item 1.01 above in an aggregate  principal amount
of $1,500,000.  The promissory  notes bear interest at the rate of 7% per annum.
Principal and accrued interest thereunder are due and payable on April 3, 2007.
ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS

      (c)   Exhibits

            Exhibit No.                Description
            -----------                -----------
            10.166           Amendment to 2005 Credit Facility.
SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: Lake Oswego, Oregon
      December 6, 2005

                                       Calypte Biomedical Corporation

                                       By: /s/ Theodore R. Gwin
                                           ---------------------------
                                           Theodore R. Gwin
                                           Chief Financial Officer